Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04852328RecruitingPhase 2
Testing CUE-101 schedules before treatment for HPV16 throat cancer
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
St Louis, MissouriAges 18 years+ - NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+ - NCT04806412Recruiting
Gene testing in lung cancer fluid samples
This study looks at fluid from around the lungs (pleural fluid) to find gene changes (oncodrivers) in people with non-small cell lung cancer. The goal is to see if this fluid can replace a tissue biopsy for testing.
Næstved, Region SjællandAges 18 years+ - NCT04784052RecruitingPhase 1/Phase 2
Briquilimab with reduced donor stem cell transplant for Fanconi anemia
This study tests whether a reduced-intensity donor stem cell transplant (with briquilimab as part of the conditioning) can safely treat bone marrow failure in people with Fanconi anemia. It may help by lowering how much intensive treatment is needed before the transplant, while still helping the donor cells grow.
Stanford, CaliforniaAges 2 years+ - NCT04853342RecruitingPhase 3
Furmonertinib after lung tumor removal for EGFR-mutated lung cancer
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Suzhou, JiangsuAges 18–75 - NCT04838171Recruiting
Study of White Blood Cells in Donors and Patients
This study looks at white blood cells (the body’s immune cells) to learn more about how they behave in health and/or illness. Participation may help researchers understand immune-related changes and support future treatments.
LondonAges Any age - NCT01245179RecruitingPhase 1
Panobinostat for adults with severe sickle cell
This early-phase study tests panobinostat, a medicine aimed at reducing sickle-cell problems, in adults with severe disease. It’s mainly looking at safety and whether it can improve blood-related issues that drive pain and complications.
Augusta, GeorgiaAges 18 years+ - NCT03858777Recruiting
Blood test for heart inflammation in sarcoidosis
This study checks whether a blood “cell-free DNA” test can show when the heart is inflamed in people with cardiac sarcoidosis. It may help doctors detect active heart involvement earlier and track how disease is doing.
Iowa City, IowaAges 18 years+ - NCT04762459Enrolling by invitationPhase 3
Almonertinib after lung tumor surgery, with or without chemo
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Beijing, Beijing MunicipalityAges 18–130 - NCT04690374Recruiting
Registry to Track Health Information in Desmoplastic Tumor
This registry collects health information from people diagnosed with desmoplastic small round cell tumor. Your information helps doctors and researchers better understand the illness over time.
New York, New YorkAges Any age - NCT04723095Recruiting
Cervical neuroendocrine cancer registry for past and present patients
This study builds a registry (a secure database) of people who have had cervical neuroendocrine cancer, including small cell or large cell types. It helps researchers learn more about these cancers and may improve future care and research planning.
Houston, TexasAges Any age - NCT04693377Recruiting
Freezing tumor treatment plus targeted radiation for painful bone spread
This study tests whether combining a “freezing” procedure (cryoablation) with focused external radiation (SBRT) can reduce pain from bone metastases. It’s for people with certain cancers that have spread to bone and are having significant pain in a specific bone spot.
Houston, TexasAges 18 years+ - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT04744116RecruitingEarly Phase 1
Cord blood cell therapy added to ruxolitinib for steroid-resistant GVHD
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
Houston, TexasAges 12–80 - NCT04691622RecruitingPhase 1
Treat chronic norovirus using donor immune cells
This Phase 1 study tests whether giving immune cells made from a donor can help children and adults with long-lasting (chronic) norovirus infection. It’s aimed at people whose immune system is weakened after a stem cell transplant, solid organ transplant, or due to primary immune problems.
Washington D.C., District of ColumbiaAges 3 months–80 years - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21 - NCT04657822RecruitingPhase 4
Crizanlizumab rollover study for people with sickle cell disease
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
Birmingham, AlabamaAges 6 months–100 years - NCT04628585Enrolling by invitation
Follow-up for people with sickle cell treated with gene therapy
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
Birmingham, AlabamaAges 2–53 - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Gilbert, ArizonaAges 18–70 - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT04623424Recruiting
Study gut bacteria during stem cell transplant
This study looks at changes in your gut bacteria (microbiome) around the time of stem cell transplant. The goal is to understand how these bacteria relate to transplant outcomes, which may help doctors improve care in the future.
Detroit, MichiganAges 18–80 - NCT04650568Enrolling by invitation
Stem cell treatment after ACL ligament surgery
This trial studies whether adding mesenchymal stem cells during ACL (knee ligament) reconstruction helps the knee heal better. You might be eligible if your ACL injury is recent and you’re having a specific type of graft surgery.
Chicago, IllinoisAges 18–60 - NCT04299646RecruitingPhase 2
Stereotactic radiation for limited spread in kidney cancer
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
AlbiAges 18 years+ - NCT04499053RecruitingPhase 2
Durvalumab and tremelimumab with chemotherapy for advanced lung cancer in HIV
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.